Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer with ALK Translocation

LESSONS LEARNED: This study evaluating first‐line crizotinib plus pembrolizumab in patients with anaplastic lymphoma kinase (ALK)–positive advanced non‐small cell lung cancer (NSCLC) was terminated early because increased availability of second‐generation ALK inhibitors resulted in difficulty identi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Patel, Sandip Pravin, Pakkala, Suchita, Pennell, Nathan A., Reckamp, Karen L., Lanzalone, Silvana, Polli, Anna, Tarazi, Jamal, Robert‐Vizcarrondo, Francisco
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356710/
https://ncbi.nlm.nih.gov/pubmed/32048771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0034
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados